Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Selegiline

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Selegiline. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-001261-42 Sponsor Protocol Number: 3002 Start Date*: 2006-05-18
    Sponsor Name:Evotec NeuroSciences GmbH
    Full Title: Assessment of Inhibition of Brain MAO-B by EVT 301 after Repeated Dosing to Steady-state in Patients with Alzheimer’s Disease and in Elderly Control Subjects
    Medical condition: Subjects with probable Alzheimer's Disease and healthy voulunteers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-000335-17 Sponsor Protocol Number: MPR001 Start Date*: 2014-10-28
    Sponsor Name:Research and Development University Hospital of North Staffordshire [...]
    1. Research and Development University Hospital of North Staffordshire
    2. Keele University
    Full Title: The Effect of Rotigotine on Memory in Idiopathic Parkinson's Disease without Cognitive Impairment
    Medical condition: Idiopathic Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002650-59 Sponsor Protocol Number: SP824 Start Date*: 2005-02-03
    Sponsor Name:SCHWARZ BIOSCIENCES
    Full Title: A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching subjects from ropinerole, pramipexole or cabergoline to the rotigotine transdermal system and its ef...
    Medical condition: Idiopathic Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002598-21 Sponsor Protocol Number: SP826 Start Date*: 2004-12-22
    Sponsor Name:Schwarz Biosciences GmbH
    Full Title: A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Pa...
    Medical condition: Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002500-91 Sponsor Protocol Number: RPC01-3001 Start Date*: 2015-10-12
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (Completed) ES (Completed) BG (Completed) SK (Completed) GR (Completed) PL (Completed) LV (Completed) EE (Completed) LT (Completed) PT (Completed) SE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-006033-32 Sponsor Protocol Number: S308.3.001 Start Date*: 2006-04-20
    Sponsor Name:Solvay Pharmaceuticals
    Full Title: A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early St...
    Medical condition: Parkinson's Disease Early Stage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004112-51 Sponsor Protocol Number: V1512-2PD01 Start Date*: 2006-11-14
    Sponsor Name:VERNALIS DEVELOPMENT LIMITED
    Full Title: A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s ...
    Medical condition: Parkinson s disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020769-25 Sponsor Protocol Number: CECILE Start Date*: 2010-08-10
    Sponsor Name:CHU de Poitiers
    Full Title: Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10034006 Parkinson's disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012529-12 Sponsor Protocol Number: 0827703 Start Date*: 2009-06-10
    Sponsor Name:CHU de Toulouse
    Full Title: A randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease
    Medical condition: parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004290-19 Sponsor Protocol Number: SP873 Start Date*: 2006-01-25
    Sponsor Name:Schwarz Biosciences GmbH
    Full Title: A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in sub...
    Medical condition: advanced-stage, idiopathic Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005140-89 Sponsor Protocol Number: TVP-1012-120-TYR Start Date*: 2006-12-11
    Sponsor Name:TEVA Pharmaceuticals Industries Ltd
    Full Title: A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY S...
    Medical condition: This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson's Disease (PD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004447-11 Sponsor Protocol Number: VR040/2/008 Start Date*: Information not available in EudraCT
    Sponsor Name:Vectura Limited
    Full Title: A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effe...
    Medical condition: Unpredictable motor fluctuation or “On-Off” or “Wearing-Off” Effects Fluctuating associated with Idiopathic Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    11 10067209 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000678-57 Sponsor Protocol Number: S308.3.003 Start Date*: 2007-06-18
    Sponsor Name:Solvay pharmaceuticals
    Full Title: A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Pa...
    Medical condition: Parkinson 's Disease early stage
    Disease: Version SOC Term Classification Code Term Level
    8.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PT (Completed) EE (Completed) LT (Completed) DE (Completed) FR (Completed) NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000801-64 Sponsor Protocol Number: BTG001 Start Date*: 2013-02-09
    Sponsor Name:University Hospital of North Staffordshire [...]
    1. University Hospital of North Staffordshire
    2. Keele University
    Full Title: A Phase IV Acceptability and Feasibility Trial of the Effects of Medication on Memory in Idiopathic Nondementing Parkinson’s Disease.
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000056-42 Sponsor Protocol Number: SP0919 Start Date*: 2011-10-07
    Sponsor Name:UCB Celltech, UK - Registered Branch of UCB Pharma SA
    Full Title: A MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECTS OF ROTIGOTINE ON SLEEP EFFICIENCY IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE
    Medical condition: Advanced Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017238-39 Sponsor Protocol Number: IPX066-B09-06 Start Date*: 2010-09-15
    Sponsor Name:Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
    Full Title: A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease
    Medical condition: Idiopathic Parkinson’s Disease (paralysis agitans)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020299-42 Sponsor Protocol Number: KKS-135 Start Date*: 2011-08-30
    Sponsor Name:Philipps-University Marburg
    Full Title: A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD)
    Medical condition: Early PD subjects within 18 months of diagnosis and not expected to require dopamine agonist or levodopa therapy for 1 year, with Hoehn and Yahr stage <2, with stable (>2 months) MAO-B inhibitor th...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004943-12 Sponsor Protocol Number: S308.3.010 Start Date*: 2008-11-24
    Sponsor Name:Solvay Pharmaceuticals B.V.
    Full Title: The Rubens Study: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration...
    Medical condition: Early Stage Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001755-36 Sponsor Protocol Number: 2939117 Start Date*: 2006-08-09
    Sponsor Name:Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
    Full Title: Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodop...
    Medical condition: Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006752-35 Sponsor Protocol Number: SP889 Start Date*: 2007-05-09
    Sponsor Name:Schwarz Biosciences GmbH
    Full Title: RECOVER: RANDOMIZED EVALUATION OF THE 24-HOUR COVERAGE: EFFICACY OF ROTIGOTINE PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-H...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Prematurely Ended) ES (Completed) HU (Completed) IT (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 15:54:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA